HC Wainwright Reiterates Buy Rating for Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $45.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 135.73% from the stock’s previous close. SMMT has been […]
More Stories
DOJ Sues Connecticut, City of New Haven Over Sanctuary Policies
By Jackson Richman The U.S. Department of Justice (DOJ) sued Connecticut and the City of New Haven on April 13...
Israel–Lebanon Talks Conclude With Signs of Progress But No Ceasefire Deal
By Ryan Morgan U.S. Secretary of State Marco Rubio hosted the Israeli and Lebanese ambassadors to the United States for...
DEI Practices Reduce Productivity, Cost $94 Billion Annually: White House Economic Report
By Travis Gillmore WASHINGTON—Diversity, equity, and inclusion practices negatively impacted the U.S. economy, according to the 2026 White House Economic...
Fauci Deputy Who Declined COVID-19 Vaccine Feared Retaliation: Emails
By Zachary Stieber A top government doctor who declined to receive a COVID-19 vaccine in 2021 was worried he would...
20+ SEO Checklist For Blog Posts: Read Before Publishing
You wrote a fantastic blog. What’s next? Publishing blogs without optimizing them for SEO is like starting a shop without...
US Military Blockade on Iranian Ports Goes Into Effect, Maritime Group Says
By Jack Phillips A scheduled U.S. naval blockade of the Strait of Hormuz and nearby waters started at 10 a.m....